TP53 and cancer: In addition, seroreactivity to the cancer autoantigen p53 has also been evaluated by using the most frequent p53 point mutants found in cancer and different N-terminal and C-terminal deletions of the protein, with the aim of identifying cryptic or masked epitopes [31].